Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 2
2010 1
2014 1
2016 1
2017 2
2018 1
2019 6
2020 6
2021 4
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Axillary nodal disease burden is not associated with an elevated 21-gene recurrence score in post-menopausal women presenting with a clinically negative axilla.
Botty van den Bruele A, Paul MA, Thomas SM, Sammons SL, DiNome ML, Plichta JK, Record SM, Woriax H, Chiba A, Rosenberger LH, Hwang ES. Botty van den Bruele A, et al. Among authors: sammons sl. Am J Surg. 2024 Feb 6:S0002-9610(24)00067-9. doi: 10.1016/j.amjsurg.2024.02.005. Online ahead of print. Am J Surg. 2024. PMID: 38350748
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
Tan TJ, Sammons S, Im YH, She L, Mundy K, Bigelow R, Traina TA, Anders C, Yeong J, Renzulli E, Kim SB, Dent R. Tan TJ, et al. Among authors: sammons s. Clin Cancer Res. 2024 Apr 1;30(7):1240-1247. doi: 10.1158/1078-0432.CCR-23-2513. Clin Cancer Res. 2024. PMID: 38236575 Free PMC article. Clinical Trial.
APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.
Sammons S, Raskina K, Danziger N, Alder L, Schrock AB, Venstrom JM, Knutson KL, Thompson EA, McGregor K, Sokol E, Chumsri S. Sammons S, et al. JCO Precis Oncol. 2022 Oct;6:e2200149. doi: 10.1200/PO.22.00149. JCO Precis Oncol. 2022. PMID: 36315915 Free PMC article.
37 results